108 related articles for article (PubMed ID: 32940666)
21. ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma.
Zhang L; Zheng Y; Chien W; Ziman B; Billet S; Koeffler HP; Lin DC; Bhowmick NA
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001638
[TBL] [Abstract][Full Text] [Related]
22. The prognostic and potentially immunomodulatory role of cartilage oligomeric matrix protein in patients with gastric and esophageal adenocarcinoma.
Papadakos KS; Gorji-Bahri G; Gialeli C; Hedner C; Hagerling C; Svensson MC; Jeremiasen M; Borg D; Fristedt R; Jirström K; Blom AM
Cancer Immunol Immunother; 2024 Apr; 73(5):93. PubMed ID: 38563861
[TBL] [Abstract][Full Text] [Related]
23. Clinical Significance and Prognostic Implications of Discontinuous Growth Pattern in Esophageal Adenocarcinoma: A Multi-Institutional Study.
Kmeid M; Lee G; Yang Z; Pacheco R; Lin J; Patil DT; Youssef M; Zhang Q; Alkashash AM; Li J; Lee H
Am J Surg Pathol; 2024 Apr; 48(4):447-457. PubMed ID: 38238961
[TBL] [Abstract][Full Text] [Related]
24. Fetal gut cell-like differentiation in esophageal adenocarcinoma defines a rare tumor subtype with therapeutically relevant claudin-6 positivity and SWI/SNF gene alteration.
Kraemer M; Zander T; Alakus H; Buettner R; Lyu SI; Simon AG; Schroeder W; Bruns CJ; Quaas A
Sci Rep; 2024 Jun; 14(1):13474. PubMed ID: 38866822
[TBL] [Abstract][Full Text] [Related]
25. Sex disparities revealed by single-cell and bulk sequencing and their impacts on the efficacy of immunotherapy in esophageal cancer.
Yan H; Huang J; Li Y; Zhao B
Biol Sex Differ; 2024 Mar; 15(1):22. PubMed ID: 38491510
[TBL] [Abstract][Full Text] [Related]
26. In silico analyses of pan-squamous cell carcinoma unveiled the immunological implications of MRPL13, which had previously been under-recognized.
Liang Y; He S; Tan Y; Liu Q; Zhao F; Liu T; Huang C; Lu X; Zheng S
Heliyon; 2024 Jan; 10(1):e23582. PubMed ID: 38187248
[TBL] [Abstract][Full Text] [Related]
27. Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM; Chadwick JA; Owen RP; White MJ; Kaplinsky J; Peneva I; Frangou A; Xie PF; Chang J; Roth A; Amess B; James SA; Rei M; Fuchs HS; McCann KJ; Omiyale AO; Jacobs BA; Lord SR; Norris-Bulpitt S; Dobbie ST; Griffiths L; Ramirez KA; Ricciardi T; Macri MJ; Ryan A; Venhaus RR; Van den Eynde BJ; Karydis I; Schuster-Böckler B; Middleton MR; Lu X;
Cancer Cell; 2023 Jul; 41(7):1222-1241.e7. PubMed ID: 37433281
[TBL] [Abstract][Full Text] [Related]
28. Patient-derived tumor models: a suitable tool for preclinical studies on esophageal cancer.
Liang F; Xu H; Cheng H; Zhao Y; Zhang J
Cancer Gene Ther; 2023 Nov; 30(11):1443-1455. PubMed ID: 37537209
[TBL] [Abstract][Full Text] [Related]
29. The immune landscape of esophageal cancer.
Huang TX; Fu L
Cancer Commun (Lond); 2019 Nov; 39(1):79. PubMed ID: 31771653
[TBL] [Abstract][Full Text] [Related]
30. Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells.
Quigley DA; Kristensen V
Mol Oncol; 2015 Dec; 9(10):2054-62. PubMed ID: 26607741
[TBL] [Abstract][Full Text] [Related]
31. Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies.
Hathaway CA; Conejo-Garcia JR; Fridley BL; Rosner B; Saeed-Vafa D; Moran Segura C; Nguyen JV; Hecht JL; Sasamoto N; Terry KL; Tworoger SS; Townsend MK
Cancer Epidemiol Biomarkers Prev; 2023 Jun; 32(6):848-853. PubMed ID: 36940177
[TBL] [Abstract][Full Text] [Related]
32. B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies.
Schlößer HA; Thelen M; Lechner A; Wennhold K; Garcia-Marquez MA; Rothschild SI; Staib E; Zander T; Beutner D; Gathof B; Gilles R; Cukuroglu E; Göke J; Shimabukuro-Vornhagen A; Drebber U; Quaas A; Bruns CJ; Hölscher AH; Von Bergwelt-Baildon MS
Oncoimmunology; 2019; 8(1):e1512458. PubMed ID: 30546950
[TBL] [Abstract][Full Text] [Related]
33. FABP6 serves as a new therapeutic target in esophageal tumor.
Zhang D; Zhao F; Liu H; Guo P; Li Z; Li S
Aging (Albany NY); 2024 Jan; 16(2):1640-1662. PubMed ID: 38277205
[TBL] [Abstract][Full Text] [Related]
34. Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of oesophagael adenocarcinoma.
Barroux M; Househam J; Lakatos E; Ronel T; Baker AM; Salié H; Mossner M; Smith K; Kimberley C; Nowinski S; Berner A; Gunasri V; Jansen M; Caravagna G; Steiger K; Slotta-Huspenina J; Weichert W; Alberstmeier M; Chain B; Friess H; Bengsch B; Schmid R; Siveke J; Quante M; Graham T
Res Sq; 2023 Apr; ():. PubMed ID: 37090678
[TBL] [Abstract][Full Text] [Related]
35. Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses.
Imamura Y; Toihata T; Haraguchi I; Ogata Y; Takamatsu M; Kuchiba A; Tanaka N; Gotoh O; Mori S; Nakashima Y; Oki E; Mori M; Oda Y; Taguchi K; Yamamoto M; Morita M; Yoshida N; Baba H; Mine S; Nunobe S; Sano T; Noda T; Watanabe M
Int J Cancer; 2021 Mar; 148(5):1260-1275. PubMed ID: 32997798
[TBL] [Abstract][Full Text] [Related]
36. A signature of seven immune-related genes predicts overall survival in male gastric cancer patients.
Xu X; Lu Y; Wu Y; Wang M; Wang X; Wang H; Chen B; Li Y
Cancer Cell Int; 2021 Feb; 21(1):117. PubMed ID: 33602220
[TBL] [Abstract][Full Text] [Related]
37. An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer.
Wang JB; Li P; Liu XL; Zheng QL; Ma YB; Zhao YJ; Xie JW; Lin JX; Lu J; Chen QY; Cao LL; Lin M; Liu LC; Lian NZ; Yang YH; Huang CM; Zheng CH
Nat Commun; 2020 Dec; 11(1):6352. PubMed ID: 33311518
[TBL] [Abstract][Full Text] [Related]
38. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer.
Bassez A; Vos H; Van Dyck L; Floris G; Arijs I; Desmedt C; Boeckx B; Vanden Bempt M; Nevelsteen I; Lambein K; Punie K; Neven P; Garg AD; Wildiers H; Qian J; Smeets A; Lambrechts D
Nat Med; 2021 May; 27(5):820-832. PubMed ID: 33958794
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Kelly RJ; Ajani JA; Kuzdzal J; Zander T; Van Cutsem E; Piessen G; Mendez G; Feliciano J; Motoyama S; Lièvre A; Uronis H; Elimova E; Grootscholten C; Geboes K; Zafar S; Snow S; Ko AH; Feeney K; Schenker M; Kocon P; Zhang J; Zhu L; Lei M; Singh P; Kondo K; Cleary JM; Moehler M;
N Engl J Med; 2021 Apr; 384(13):1191-1203. PubMed ID: 33789008
[TBL] [Abstract][Full Text] [Related]
40. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment.
Zheng Y; Chen Z; Han Y; Han L; Zou X; Zhou B; Hu R; Hao J; Bai S; Xiao H; Li WV; Bueker A; Ma Y; Xie G; Yang J; Chen S; Li H; Cao J; Shen L
Nat Commun; 2020 Dec; 11(1):6268. PubMed ID: 33293583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
